Nothing Special   »   [go: up one dir, main page]

GB9902591D0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
GB9902591D0
GB9902591D0 GBGB9902591.8A GB9902591A GB9902591D0 GB 9902591 D0 GB9902591 D0 GB 9902591D0 GB 9902591 A GB9902591 A GB 9902591A GB 9902591 D0 GB9902591 D0 GB 9902591D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9902591.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Priority to GBGB9902591.8A priority Critical patent/GB9902591D0/en
Publication of GB9902591D0 publication Critical patent/GB9902591D0/en
Priority to GBGB0001662.6A priority patent/GB0001662D0/en
Priority to ARP000100409A priority patent/AR025512A1/en
Priority to JP2000596938A priority patent/JP2002536332A/en
Priority to PT00901744T priority patent/PT1150678E/en
Priority to EEP200100405A priority patent/EE05556B1/en
Priority to AU23047/00A priority patent/AU763970B2/en
Priority to EP07008956A priority patent/EP1897546B1/en
Priority to IL14473000A priority patent/IL144730A0/en
Priority to NZ52541900A priority patent/NZ525419A/en
Priority to SK5109-2008A priority patent/SK287792B6/en
Priority to ES00901744T priority patent/ES2286995T3/en
Priority to SK1110-2001A priority patent/SK286854B6/en
Priority to DK07008956.0T priority patent/DK1897546T3/en
Priority to PT07008956T priority patent/PT1897546E/en
Priority to EEP201200015A priority patent/EE05621B1/en
Priority to KR1020017009907A priority patent/KR100699757B1/en
Priority to SI200031063T priority patent/SI1897546T1/en
Priority to ES07008956T priority patent/ES2352803T3/en
Priority to CA002368186A priority patent/CA2368186C/en
Priority to CZ20012806A priority patent/CZ302881B6/en
Priority to CZ20110341A priority patent/CZ302893B6/en
Priority to PL350312A priority patent/PL198098B1/en
Priority to BR0007996-0A priority patent/BR0007996A/en
Priority to DE60035575T priority patent/DE60035575T2/en
Priority to PCT/GB2000/000280 priority patent/WO2000045818A1/en
Priority to DE60045168T priority patent/DE60045168D1/en
Priority to TR2001/02229T priority patent/TR200102229T2/en
Priority to SI200030962T priority patent/SI1150678T1/en
Priority to EP00901744A priority patent/EP1150678B1/en
Priority to CNB008034974A priority patent/CN1196488C/en
Priority to DK00901744T priority patent/DK1150678T3/en
Priority to MXPA01007821A priority patent/MXPA01007821A/en
Priority to AT00901744T priority patent/ATE367162T1/en
Priority to RU2001124665/15A priority patent/RU2239456C2/en
Priority to US09/889,409 priority patent/US6894058B1/en
Priority to AT07008956T priority patent/ATE485823T1/en
Priority to NZ513061A priority patent/NZ513061A/en
Priority to NZ536433A priority patent/NZ536433A/en
Priority to HU0105138A priority patent/HU227642B1/en
Priority to TW089101895A priority patent/TWI230067B/en
Priority to MYPI20000412A priority patent/MY138289A/en
Priority to ZA200105885A priority patent/ZA200105885B/en
Priority to IS6016A priority patent/IS2793B/en
Priority to NO20013812A priority patent/NO330400B1/en
Priority to IL144730A priority patent/IL144730A/en
Priority to HK02103012A priority patent/HK1041223A1/en
Priority to US10/935,747 priority patent/US20050209128A1/en
Priority to CY20071101207T priority patent/CY1106879T1/en
Priority to US12/222,534 priority patent/US20090186908A1/en
Priority to HK08109378.5A priority patent/HK1118209A1/en
Priority to IL208330A priority patent/IL208330A0/en
Priority to CY20101101157T priority patent/CY1110992T1/en
Priority to US13/048,377 priority patent/US20120041010A1/en
Priority to IS8978A priority patent/IS2820B/en
Priority to JP2011213694A priority patent/JP2012051898A/en
Priority to JP2013239770A priority patent/JP2014065718A/en
Ceased legal-status Critical Current

Links

GBGB9902591.8A 1999-02-06 1999-02-06 Pharmaceutical compositions Ceased GB9902591D0 (en)

Priority Applications (57)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB0001662.6A GB0001662D0 (en) 1999-02-06 2000-01-26 Pharmaceutical compositions
ARP000100409A AR025512A1 (en) 1999-02-06 2000-01-31 A METHOD TO TREAT NEUROPATHIES AND TO IMPROVE NERVOUS DRIVING SPEED OR NERVOUS BLOOD FLOW; USE OF A STATIN TYPE DRUG AND A PHARMACEUTICAL COMBINATION AND COMPOSITION
JP2000596938A JP2002536332A (en) 1999-02-06 2000-02-01 Use of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the manufacture of a medicament for the treatment of diabetic neuropathy
PT00901744T PT1150678E (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
EEP200100405A EE05556B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme as a reductase inhibitor in the preparation of a medicament for the treatment of diabetic neuropathy
AU23047/00A AU763970B2 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
EP07008956A EP1897546B1 (en) 1999-02-06 2000-02-01 Combined compositions comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
IL14473000A IL144730A0 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
NZ52541900A NZ525419A (en) 1999-02-06 2000-02-01 Pharmaceutical formulations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid
SK5109-2008A SK287792B6 (en) 1999-02-06 2000-02-01 Pharmaceutical combinations and compositions comprising (E) -7- {4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl} - (3R, 5S) -3,5 dihydroxyhept-6-enoic acid
ES00901744T ES2286995T3 (en) 1999-02-06 2000-02-01 USE OF INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARILE COENZYME TO REDUCTASE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETIC NEUROPATHY.
SK1110-2001A SK286854B6 (en) 1999-02-06 2000-02-01 Use of statin drug for the manufacture of a medicament for the treatment of diabetic neuropathy
DK07008956.0T DK1897546T3 (en) 1999-02-06 2000-02-01 Combined compositions comprising (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3r, 5s] -3,5-dihydroxyhept-6 -enoinsyre
PT07008956T PT1897546E (en) 1999-02-06 2000-02-01 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
EEP201200015A EE05621B1 (en) 1999-02-06 2000-02-01 Combination compositions containing (E) -7- [4- (4-fluorophen l) -6-isopropyl-2- [methyl (methylsulfonyl) amino] p rimidin-5-l] - (3R, 5S) -3,5-dihydroxy hept-6-enoic acid
KR1020017009907A KR100699757B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
SI200031063T SI1897546T1 (en) 1999-02-06 2000-02-01 Combined compositions comprising (E)-7-?á4-(4-fluorophenyl)-6-isopropyl-2-?ámethyl(methylsulfonyl)amino?åpyrimidin-5-yl?å(3r,5s)-3,5-dihydroxyhept-6-enoic acid
ES07008956T ES2352803T3 (en) 1999-02-06 2000-02-01 COMBINED COMPOSITIONS INCLUDING ACID (E) -7- [4- (4-FLUOROPHENYL) -6-ISOPROPIL-2- [METHYL (METILSULFONYL) AMINO] PIRIMIDIN-5-IL] (3R, 5S) -3,5-DIHIDROXIHEPT -6-ENOICO.
CA002368186A CA2368186C (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
CZ20012806A CZ302881B6 (en) 1999-02-06 2000-02-01 Statin medicament for treating diabetic neuropathy
CZ20110341A CZ302893B6 (en) 1999-02-06 2000-02-01 Pharmaceutical combination comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5- dihydroxyhept-6-enoic acid and pharmaceutical composition as well as individual dosage form containing said acid
PL350312A PL198098B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
BR0007996-0A BR0007996A (en) 1999-02-06 2000-02-01 Methods for the treatment of empathic neuropathy suffering from diabetes, and for improved nerve conduction or blood flow velocity in a patient suffering from diabetic deneuropathy, use of a statin drug, pharmaceutical combination, and pharmaceutical composition
DE60035575T DE60035575T2 (en) 1999-02-06 2000-02-01 USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE60045168T DE60045168D1 (en) 1999-02-06 2000-02-01 Combination preparations containing (E) -7-A4- (4-fluorophenyl) -6-isopropyl-2-methyl (methylsulfonyl) amino-pyrimidin-5-yl-1 (3r, 5s) -3,5-dihydroxyhept-6-enoic acid
TR2001/02229T TR200102229T2 (en) 1999-02-06 2000-02-01 The use of 3-Hydroxy-2-methylglutaryl coenzyme A reductase inhibitors in the manufacture of a medicament for the treatment of diabetic retinopathy.
SI200030962T SI1150678T1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
EP00901744A EP1150678B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
CNB008034974A CN1196488C (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DK00901744T DK1150678T3 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the manufacture of a medicament for the treatment of diabetic neuropathy
MXPA01007821A MXPA01007821A (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy.
AT00901744T ATE367162T1 (en) 1999-02-06 2000-02-01 USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS FOR PRODUCING A MEDICATION FOR THE TREATMENT OF DIABETIC NEUROPATHY
RU2001124665/15A RU2239456C2 (en) 1999-02-06 2000-02-01 Application of 3-hydroxy-3-methtylglutaryl-coenzyme a reductase inhibitors in producing medicinal agent for treatment of diabetic neuropathy
US09/889,409 US6894058B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
AT07008956T ATE485823T1 (en) 1999-02-06 2000-02-01 COMBINATION PREPARATIONS CONTAINING (E)-7-Ä4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-
NZ513061A NZ513061A (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the treatment of diabetic neuropathy
NZ536433A NZ536433A (en) 1999-02-06 2000-02-01 Pharmaceutical formulations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid
HU0105138A HU227642B1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
TW089101895A TWI230067B (en) 1999-02-06 2000-02-03 Pharmaceutical compositions for treating diabetic neuropathy or improving nerve conduction velocity or nerve blood flow comprising statin drug
MYPI20000412A MY138289A (en) 1999-02-06 2000-02-04 Pharmaceutical compositions
ZA200105885A ZA200105885B (en) 1999-02-06 2001-07-17 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy.
IS6016A IS2793B (en) 1999-02-06 2001-07-20 Use of 3-hydroxy-3-methylglutaryl auxiliary enzyme A antacid inhibitors for the manufacture of a medicament for the treatment of diabetes mellitus
NO20013812A NO330400B1 (en) 1999-02-06 2001-08-03 Use of rosuvastatin for the manufacture of a medicament for the treatment of diabetic neuropathy
IL144730A IL144730A (en) 1999-02-06 2001-08-05 Use of statin drug in the preparation of a medicament and as a medicament for the treatment of diabetic neuropathy
HK02103012A HK1041223A1 (en) 1999-02-06 2002-04-22 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicamentfor the treatment of diabetic neuropathy
US10/935,747 US20050209128A1 (en) 1999-02-06 2004-09-08 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
CY20071101207T CY1106879T1 (en) 1999-02-06 2007-09-19 USE OF INHIBITORS OF 3-HYDROXY-3-METHYLOGLUTARYL COenzyme A REDUCTION FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DIABETIC NEUROPATHY
US12/222,534 US20090186908A1 (en) 1999-02-06 2008-08-11 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
HK08109378.5A HK1118209A1 (en) 1999-02-06 2008-08-21 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6- enoic acid
IL208330A IL208330A0 (en) 1999-02-06 2010-09-21 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors ('statin drugs') and lisinopril, formulations comprising them and their use in the manufacture of medicaments and as medicaments for improving nerve conduction velocity or nerve blood flow in a non-human animal having diabetic neuropathy and for treating diabetic neuropathy in a non-human animal
CY20101101157T CY1110992T1 (en) 1999-02-06 2010-12-16 COMBINED COMPOSITIONS CONTAINING (E) -7- [4- (4-Fluorophenyl) -6-Isopropyl-2- [Methyl (Methylsulfonyl) Amino] 5-Pyridyl-5-3-yl) 6-SODIUM ACID
US13/048,377 US20120041010A1 (en) 1999-02-06 2011-03-15 Pharmaceutical combination of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3r,5s)-3,5-dihydroxyhept-6-enoic acid and candesartan
IS8978A IS2820B (en) 1999-02-06 2011-08-23 Compositions comprising (E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3,5- dihydroxyhept-6-enoic acid
JP2011213694A JP2012051898A (en) 1999-02-06 2011-09-29 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for manufacturing medicament for treatment of diabetic neuropathy
JP2013239770A JP2014065718A (en) 1999-02-06 2013-11-20 Use of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
GB9902591D0 true GB9902591D0 (en) 1999-03-24

Family

ID=10847177

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9902591.8A Ceased GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions

Country Status (1)

Country Link
GB (1) GB9902591D0 (en)

Similar Documents

Publication Publication Date Title
HUP0202513A2 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
PL351387A1 (en) Pharmaceutical composition
HU9901606D0 (en) Pharmaceutical compositions
HK1044476A1 (en) Medicinal compositions
GB9827996D0 (en) Pharmaceutical Compositions
HUP0103507A3 (en) Pharmaceutical compositions comprising 2-quinolones
GB9923436D0 (en) Pharmaceutical compositions
EP1166786A4 (en) Medicinal compositions
AU3556400A (en) Pharmaceutical compositions
GB9904163D0 (en) Pharmaceutical compositions
GB9809213D0 (en) Pharmaceutical compositions
GB9911017D0 (en) Pharmaceutical compositions
AU6460200A (en) Pharmaceutical compositions
HK1030552A1 (en) Pharmaceutical compositions
GB9904911D0 (en) Pharmaceutical compositions
AU6460100A (en) Pharmaceutical compositions
GB9902651D0 (en) Pharmaceutical compositions
IL130325A0 (en) Pharmaceutical compositions comprising allicin
GB9806487D0 (en) Pharmaceutical compositions
GB9920652D0 (en) Pharmaceutical compositions
GB9902594D0 (en) Pharmaceutical compositions
GB9902591D0 (en) Pharmaceutical compositions
GB9916210D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)